Invention Grant
US09346813B2 Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
有权
取代的吡咯并[2,3-d]嘧啶酮作为CDK9激酶抑制剂
![Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors](/docs/US/2016-05-24/US09346813B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
- Patent Title (中): 取代的吡咯并[2,3-d]嘧啶酮作为CDK9激酶抑制剂
-
Application No.: US14207868Application Date: 2014-03-13
-
Publication No.: US09346813B2Publication Date: 2016-05-24
- Inventor: Alan S. Florjancic , Yunsong Tong , Thomas D. Penning , Andrew J. Souers , Rajeev Goswami , Zhi-Fu Tao
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Agent Changxia Sun
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D239/70 ; C07D487/04
![Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors](/abs-image/US/2016/05/24/US09346813B2/abs.jpg.150x150.jpg)
Abstract:
Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
Public/Granted literature
- US20140275004A1 PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS Public/Granted day:2014-09-18
Information query
IPC分类:
